Most Recent
Despite noting that a class action trial and appeal were "unusual", a judge overseeing a long-running class action against Ford has refused an application to send a notice to group members about a coming appeal in the case.
A judge has declined to pass on a senior barrister’s $18,000 cancellation fee as part of an adverse costs order for a vacated trial, noting that such fees are not standard or common practice.
The largest shareholder in payday lender Nimble has lost its challenge to a decision blocking it from accessing company documents about an impending debt refinance, with an appeals court finding the investor’s concerns had “an air of commercial unreality”.
The settlement figure in a class action against a unit of Suncorp Group has been revealed as $33 million, and super members are set to share in the net sum of $14 million, or 42.5 per cent of the deal.
Facebook owner Meta is fighting for broad non-publication orders in its battle with the ACCC over material it says could prejudice jury members in criminal proceedings by mining magnate Andrew Forrest.
A unit of Suncorp Group has reached an in-principle settlement in a class action over alleged conflicted remuneration on the first day of an expected 25-day trial.
Ford is seeking an extended hearing of its appeal from a class action judgment in favour of 185,000 vehicle owners over their allegedly defective cars, saying a “significant excavation” of the ruling is now in order.
The Full Federal Court has found that a landmark NSW Court of Appeal decision barring group members from being notified of future class closure orders at settlement was "plainly wrong" and that the court has the power to make the orders.
A judge has questioned whether the lead applicant in a class action over sleep apnea machines with alleged safety defects was “appropriately resourced” to run the case against health tech giant Philips.
The Full Court has upheld two judgments that shortened patent term extensions granted to Merck Sharpe & Dohme and Ono Pharmaceuticals, finding the extension regime cannot be construed as achieving a "commercial outcome for a patentee".